Risk Of Death From COVID-19 Is 30% Lower When Treated With Hydroxychloroquine, Large Italian Study Finds from Natural Blaze
An observational multi-center study, coordinated by the I.R.C.C.S. Neuromed, with the participation of 33 Italian hospitals, shows that the risk of death is 30% lower for coronavirus patients treated with hydroxychloroquine
An Italian observational study contributes to the ongoing debate regarding the use of hydroxychloroquine in the current pandemic. The research, conducted on 3,451 patients treated in 33 hospitals throughout the Italian territory (list of participating centers attached), shows that the use of this drug reduces by 30% the risk of death in hospitalized patients affected by Covid-19.
Published in the European Journal of Internal Medicine, the study was coordinated by the Department of Epidemiology and Prevention of the I.R.C.C.S. Neuromed, Pozzilli, in collaboration with Mediterranea Cardiocentro, Naples, and the University of Pisa, with the participation of 33 hospitals forming the CORIST collaboration (COvid-19 RISk and Treatments). Researchers analysed data regarding current and previous diseases, therapies followed before the infection and drugs administered in the hospital specifically for the treatment of COVID-19. All this information was compared with the evolution and the final in-hospital outcome of the infection.
Now is your chance to support Gospel News Network.
We love helping others and believe that’s one of the reasons we are chosen as Ambassadors of the Kingdom, to serve God’s children. We look to the Greatest Commandment as our Powering force.
“We observed – explains Augusto Di Castelnuovo, epidemiologist at the Neuromed Department of Epidemiology and Prevention, currently at Mediterranea Cardiocentro in Naples – that patients treated with hydroxychloroquine had a 30% lower in-hospital mortality rate compared to those not receiving this treatment. Our data were subjected to extremely rigorous statistical analysis, taking into account all the variables and possible confounding factors that could come into play. The drug efficacy was evaluated in various subgroups of patients. The positive results of hydroxychloroquine treatment remained unchanged, especially in those patients showing a more evident inflammatory state at the moment of admission to hospital”.
